Mycenax Biotech Partners with RIN to Enhance ADC Development Using Advanced Linker Technology
Mycenax Biotech Inc., recognized as a leading Contract Development and Manufacturing Organization (CDMO) in biologics, has reached a significant milestone by signing a License Agreement with RIN Institute, a prominent entity based in Japan. Announced on October 31, 2025, this collaboration empowers Mycenax with the rights to leverage RIN's proprietary Val-Leu-Lys (VLK) linker technology across its CDMO services on a global scale.
The VLK linker technology developed by RIN is gaining attention for its impressive anti-tumor effectiveness combined with high stability in serum. This advancement is set to elevate the design and production of Antibody-Drug Conjugates (ADCs), a vital component in the fight against cancer. By enabling cytotoxic properties through two distinct action mechanisms within tumor environments, this linker technology also enhances the internalization of ADCs, thus making them more effective against malignancies.
Pei-Jiun Chen, CEO and President of Mycenax, expressed enthusiasm regarding the agreement, stating, "We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to provide innovative and competitive ADC solutions." This pact is expected to substantially increase Mycenax's capabilities in delivering tailored ADC products that meet the demanding standards of global pharmaceutical partners.
This partnership is built upon previously established foundations, including a Letter of Intent (LOI) signed on April 7, 2025, which set the stage for more structured cooperation aimed at pushing the boundaries of ADC innovation. With this agreement, Mycenax aims to solidify its position as a leader in the ADC domain, transforming research advancements into tangible therapeutic solutions.
Founded in January 2016, RIN Institute focuses on the development of anti-cancer antibody drugs for both therapeutic and diagnostic purposes. Established from key research by Dr. Yasuhiro Matsumura, the institute has earned its legitimacy as a spin-out biotech from the National Cancer Center (NCC) of Japan. RIN promotes productive collaboration with NCC and has advanced research projects in ADCs and novel thrombolytic fusion proteins. Their lead pipeline, involving a humanized anti-TMEM180 antibody, began its Phase 1 trial at NCC in January 2023, highlighting the institute's commitment to revolutionizing cancer treatment with innovative drugs.
As a premier CDMO in Taiwan, Mycenax provides comprehensive solutions ranging from cell line development to drug product manufacturing, boasting facilities compliant with Good Manufacturing Practices (GMP) recognized by various global regulatory agencies, including the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The integration of its ADC capabilities comes in collaboration with KriSan Biotech and Spera Pharma, enhancing site-specific conjugation and employing multi-arm linkers to meet the ever-growing global demand. Mycenax also partners with several industry players under Japan's MHLW subsidy program, broadening its biosimilar manufacturing capabilities. For further information, visit www.mycenax.com.
The VLK linker technology developed by RIN is gaining attention for its impressive anti-tumor effectiveness combined with high stability in serum. This advancement is set to elevate the design and production of Antibody-Drug Conjugates (ADCs), a vital component in the fight against cancer. By enabling cytotoxic properties through two distinct action mechanisms within tumor environments, this linker technology also enhances the internalization of ADCs, thus making them more effective against malignancies.
Pei-Jiun Chen, CEO and President of Mycenax, expressed enthusiasm regarding the agreement, stating, "We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to provide innovative and competitive ADC solutions." This pact is expected to substantially increase Mycenax's capabilities in delivering tailored ADC products that meet the demanding standards of global pharmaceutical partners.
This partnership is built upon previously established foundations, including a Letter of Intent (LOI) signed on April 7, 2025, which set the stage for more structured cooperation aimed at pushing the boundaries of ADC innovation. With this agreement, Mycenax aims to solidify its position as a leader in the ADC domain, transforming research advancements into tangible therapeutic solutions.
About RIN Institute
Founded in January 2016, RIN Institute focuses on the development of anti-cancer antibody drugs for both therapeutic and diagnostic purposes. Established from key research by Dr. Yasuhiro Matsumura, the institute has earned its legitimacy as a spin-out biotech from the National Cancer Center (NCC) of Japan. RIN promotes productive collaboration with NCC and has advanced research projects in ADCs and novel thrombolytic fusion proteins. Their lead pipeline, involving a humanized anti-TMEM180 antibody, began its Phase 1 trial at NCC in January 2023, highlighting the institute's commitment to revolutionizing cancer treatment with innovative drugs.
About Mycenax Biotech Inc.
As a premier CDMO in Taiwan, Mycenax provides comprehensive solutions ranging from cell line development to drug product manufacturing, boasting facilities compliant with Good Manufacturing Practices (GMP) recognized by various global regulatory agencies, including the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The integration of its ADC capabilities comes in collaboration with KriSan Biotech and Spera Pharma, enhancing site-specific conjugation and employing multi-arm linkers to meet the ever-growing global demand. Mycenax also partners with several industry players under Japan's MHLW subsidy program, broadening its biosimilar manufacturing capabilities. For further information, visit www.mycenax.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.